• Primmune Therapeutics Announces the Selection of PRTX007 as Its Clinical Development Candidate for COVID-19 and Oncology Indications

    1 month ago - By San Diego Biotechnology

    SAN DIEGO, March 31, 2020 /PRNewswire/ - Primmune Therapeutics announced today that it has selected PRTX007 as its lead clinical development candidate for SARS-CoV-2 and for oncology indications.
    "PRTX007 is......
    Read more ...

     

  • Mirati Therapeutics: Director , Chemical Process R & D: 2020-37

    1 month ago - By San Diego Biotechnology

    Mirati Therapeutics:
    Mirati Therapeutics, Inc. is a publicly traded San Diego based, clinical stage biotechnology company dedicated to advancing novel oncol
    San Diego, CA, United States
    ...
    Read more ...